TrialUrology2011

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.

Evan Y Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.